Cyagen Biosciences Competitors and Similar CompaniesClear all

Cyagen Biosciences's competitors and similar companies include MTM, Kirkstall and Combinati.
Cyagen Biosciences
Cyagen Biosciences
Cyagen Biosciences is a company providing custom-engineered mouse and rat models.
MTM
MTM
MTM is a research company specializing in the field of biotechnology, especially in the biomedical and agri-food sector.
Kirkstall
Kirkstall
Kirkstall is a biotechnology company specializing in products and services supporting in vitro cell culture research and the development of regular in vitro testing.
Combinati
Combinati
Combinati is a company that develops a digital polymerase chain reaction platform for detecting and quantifying rare mutations and target sequences.
Founding Date
Founding Date
2005
Founding Date
2013
Founding Date
2006
Founding Date
2016
Type
Type
Private
Type
Private
Type
Private
Type
Subsidiary
Tags
Locations
Locations
Santa Clara, US HQ
Suzhou Shi, CN
Toshima City, JP
Locations
Milano, IT HQ
Locations
Rotherham, GB HQ
York, GB
Locations
Palo Alto, US HQ
Employees
Employees
900
Employees
N/A
Employees
176% decrease
Employees
3

Funding

Latest funding round
Latest funding round
$ 41m (over 6 years ago)
Latest funding round
N/A
Latest funding round
$ 323.7k (about 10 years ago)
Latest funding round
N/A
Total funding raised
Total funding raised
$ 41m
Total funding raised
N/A
Total funding raised
$ 323.7k
Total funding raised
$ 5.8m
For sources of this data, please see the company profile

View Company Profiles

MTM
HQ
Milano, IT

MTM is a research company specializing in the field of biotechnology, especially in the biomedical and agri-food sector.

View company
Kirkstall
HQ
Rotherham, GB
Employees
17↓ 6% decrease

Kirkstall is a biotechnology company specializing in products and services supporting in vitro cell culture research and the development of regular in vitro testing.

View company
Combinati
HQ
Palo Alto, US

Combinati is a company that develops a digital polymerase chain reaction platform for detecting and quantifying rare mutations and target sequences.

View company